ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 594,07
-0,51%
Dow Jones
40 211,72
0,53%
DAX
18 526,28
-0,40%
Brent Oil
83,62
-0,85%
Bitcoin
62 961,84
-2,91%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
10/02/202018h03Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTLAPortola Pharmaceuticals Inc
08/02/202000h00GlobeNewswire Inc.Saxena White P.A. Files New Securities Fraud Class Action Complaint Against Portola Pharmaceuticals, Inc. with Expanded Class...NASDAQ:PTLAPortola Pharmaceuticals Inc
07/02/202016h59Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
05/02/202000h55Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
03/02/202017h15PR Newswire (US)WeissLaw LLP: Portola Pharmaceuticals, Inc. is the Subject of a Legal InvestigationNASDAQ:PTLAPortola Pharmaceuticals Inc
03/02/202014h30PR Newswire (US)Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical OfficerNASDAQ:PTLAPortola Pharmaceuticals Inc
30/01/202015h00Business WireThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Portola Pharmaceut...NASDAQ:PTLAPortola Pharmaceuticals Inc
27/01/202019h46PR Newswire (US)PTLA LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of its Investigation into Portola Pharmaceuticals, Inc., and Enco...NASDAQ:PTLAPortola Pharmaceuticals Inc
21/01/202021h51Business WireShareholder Alert: Robbins LLP Announces Portola Pharmaceuticals, Inc. (PTLA) Sued for Misleading ShareholdersNASDAQ:PTLAPortola Pharmaceuticals Inc
18/01/202001h17Business WirePTLA LOSSES ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Against Portola Pharmaceuticals, ...NASDAQ:PTLAPortola Pharmaceuticals Inc
17/01/202022h01Business WireThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Portola Pharmaceuticals, Inc....NASDAQ:PTLAPortola Pharmaceuticals Inc
11/01/202000h41Business WireThe Law Offices of Frank R. Cruz Announces Investigation on Behalf of Portola Pharmaceuticals, Inc., (PTLA)NASDAQ:PTLAPortola Pharmaceuticals Inc
10/01/202018h04PR Newswire (US)(PTLA) Alert: Johnson Fistel Launches Investigation into Portola Pharmaceuticals; Investors Encouraged to Contact FirmNASDAQ:PTLAPortola Pharmaceuticals Inc
09/01/202022h20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/01/202022h01PR Newswire (US)Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 MillionNASDAQ:PTLAPortola Pharmaceuticals Inc
08/01/202020h03Edgar (US Regulatory)Schedule 13gNASDAQ:PTLAPortola Pharmaceuticals Inc
23/12/201914h30PR Newswire (US)Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020NASDAQ:PTLAPortola Pharmaceuticals Inc
17/12/201914h30PR Newswire (US)Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic StrokeNASDAQ:PTLAPortola Pharmaceuticals Inc
09/12/201921h21PR Newswire (US)Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavi...NASDAQ:PTLAPortola Pharmaceuticals Inc
08/12/201918h00PR Newswire (US)Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in H...NASDAQ:PTLAPortola Pharmaceuticals Inc
15/11/201922h25PR Newswire (US)Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency PhysiciansNASDAQ:PTLAPortola Pharmaceuticals Inc
06/11/201916h07PR Newswire (US)Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual MeetingNASDAQ:PTLAPortola Pharmaceuticals Inc
05/11/201923h12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
05/11/201922h00PR Newswire (US)Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
01/11/201921h30PR Newswire (US)Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
28/10/201914h00PR Newswire (US)Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in ...NASDAQ:PTLAPortola Pharmaceuticals Inc
15/10/201914h30PR Newswire (US)Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019NASDAQ:PTLAPortola Pharmaceuticals Inc
02/10/201922h17Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
19/09/201914h20PR Newswire (US)Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of DirectorsNASDAQ:PTLAPortola Pharmaceuticals Inc
22/08/201914h30PR Newswire (US)Portola Pharmaceuticals to Participate in Two Upcoming Investor ConferencesNASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

AMEX
JETS
US Global Jets ETF
NASDAQ
MOR
MorphoSys
NASDAQ
QDROU
Quadro Acquisition One
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés